{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:38:03Z","timestamp":1793929083409,"version":"4.8.0"},"reference-count":9,"publisher":"American Society of Hematology","issue":"17","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Pediatric thrombotic thrombocytopenic purpura (TTP) is an ultrarare disease. Immune TTP (iTTP) is driven by anti-ADAMTS13 autoantibodies causing an imbalanced von Willebrand factor (VWF):ADAMTS13 axis, and rarer still in children, but potentially life-threatening. Caplacizumab is licensed for iTTP treatment in adults and adolescents aged \u226512 years who weigh \u226540\u00a0kg. There is a need to clarify whether caplacizumab can be used in younger children. We retrospectively described caplacizumab use in 16 patients under 18 years of age from the UK TTP Registry, including 4 children aged &amp;lt;12 years. For patients weighing &amp;lt;40\u00a0kg (n\u00a0=\u00a03), caplacizumab was dosed at 5\u00a0mg once dailyThe youngest patient was 33\u00a0months old at diagnosis. Plasma exchange (PEX) was used in 15 patients, with a median of 5 exchanges required before platelet count normalization (range, 2-9). One patient was managed without PEX. All patients achieved normalization of platelet count (median, 5.5\u00a0days; range, 3-28) and ADAMTS13 activity (median, 35\u00a0days; range, 8-149), with a median hospital admission of 11\u00a0days (range, 5-26). There were no refractory patients. One patient relapsed 9\u00a0months after presentation. Bleeding requiring VWF supplementation and reduction of caplacizumab use occurred in 1 patient with severe epistaxis, with no significant intracranial or gastrointestinal bleeding. We demonstrated the efficacy and safety of caplacizumab in the pediatric population, which is synonymous with the adult trial data: primarily, reduction of PEX compared with the precaplacizumab era. This has implications for the intensification and duration of admission, particularly relevant in pediatric care.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013488","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T17:08:38Z","timestamp":1720199318000},"page":"4563-4567","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Caplacizumab in pediatric immune thrombotic thrombocytopenic purpura: the UK TTP Registry experience"],"prefix":"10.1182","volume":"8","author":[{"given":"Alice","family":"Taylor","sequence":"first","affiliation":[{"name":"1Department of Paediatric Haematology, Great Ormond Street Hospital for Children National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Keogh","sequence":"additional","affiliation":[{"name":"2Department of Haematology, University College London Hospitals National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmy","family":"Dickens","sequence":"additional","affiliation":[{"name":"3Department of Paediatric Haematology, Addenbrooke\u2019s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Dutt","sequence":"additional","affiliation":[{"name":"4Department of Haematology, Royal Liverpool University Hospitals National Health Service Foundation Trust, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-0647","authenticated-orcid":false,"given":"John","family":"Grainger","sequence":"additional","affiliation":[{"name":"5Department of Haematology, Manchester University National Health Service Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rennick","family":"Gregory","sequence":"additional","affiliation":[{"name":"6Department of Haematology, Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Mapplebeck","sequence":"additional","affiliation":[{"name":"6Department of Haematology, Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Richards","sequence":"additional","affiliation":[{"name":"7Department of Paediatric Haematology, Leeds Teaching Hospitals National Health Service Trust, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Stokley","sequence":"additional","affiliation":[{"name":"8Department of Paediatric Haematology, Nottingham University Hospitals National Health Service Trust, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Styliani","family":"Salta","sequence":"additional","affiliation":[{"name":"9Department of Paediatric Haematology, University Hospitals of Leicester National Health Service Trust, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Taylor","sequence":"additional","affiliation":[{"name":"8Department of Paediatric Haematology, Nottingham University Hospitals National Health Service Trust, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Scully","sequence":"additional","affiliation":[{"name":"2Department of Haematology, University College London Hospitals National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"2024091012553277200_bib1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1146\/annurev-med-061813-013241","article-title":"ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura","volume":"66","author":"Zheng","year":"2015","journal-title":"Annu Rev Med"},{"issue":"17","key":"2024091012553277200_bib2","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2012-04-420943","article-title":"Evaluation of efficacy and safety of the anti-VWF nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura","volume":"120","author":"Callewaert","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2024091012553277200_bib3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024091012553277200_bib4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"2024091012553277200_bib5","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"issue":"14","key":"2024091012553277200_bib6","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an International Working Group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2024091012553277200_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/jcph.1991","article-title":"Caplacizumab model-based dosing recommendations in paediatric patients with acquired thrombotic thrombocytopenic purpura","volume":"62","author":"Bergstrand","year":"2022","journal-title":"J\u00a0Clin Pharmacol"},{"key":"2024091012553277200_bib8","unstructured":"European Medicines Agency\n          . Cablivi. 2018. Accessed 29 July 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/Human\/EPAR\/cablivi."},{"key":"2024091012553277200_bib9","author":"US Food & Drug Administration","year":"6  2019"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2024014730","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/17\/4563\/2241201\/blooda_adv-2024-013488-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/17\/4563\/2241201\/blooda_adv-2024-013488-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T12:55:59Z","timestamp":1725972959000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/17\/4563\/516851\/Caplacizumab-in-pediatric-immune-thrombotic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":9,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,9,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013488","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2024014730","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]}}}